Glaxosmithkline Share Price (GSK)

Show Chart Filters
Time period:
Moving Average:
Compare to:
Price 1,699.80on 15-11-2019 at 16:30:00
Change -1.40 -0.08%
Buy 1,699.00
Sell 1,698.40
Buy / Sell GSK Shares
Sponsored Financial Content
Last Trade: Sell 1,191 at 1,690.555p
Day's Volume: 11,397,458
Last Close: 1,701.20p
Open: 1,705.00p
ISIN: GB0009252882
Day's Range 1,677.80p - 1,710.40p
52wk Range: 1,408.80p - 1,796.40p
Market Capitalisation: £84,072m
VWAP: 0.00p
Shares in Issue: 4,946m

Recent Trades History Glaxosmithkline (GSK)

Buy/Sell Volume Trade Prc Trade Type Trade Time
18:45:01 - 15-Nov-19
Delayed publication
17:17:31 - 15-Nov-19
17:43:23 - 15-Nov-19
17:41:47 - 15-Nov-19
17:41:47 - 15-Nov-19
17:38:18 - 15-Nov-19
17:37:52 - 15-Nov-19
17:37:52 - 15-Nov-19
17:37:06 - 15-Nov-19
17:37:06 - 15-Nov-19

Share Price History for Glaxosmithkline

Time period:
Date Open High Low Close
14th Nov 2019 (Thu)1,724.801,734.001,694.001,699.40
13th Nov 2019 (Wed)1,732.201,753.201,731.601,737.40
12th Nov 2019 (Tue)1,719.601,739.001,718.001,733.60
11th Nov 2019 (Mon)1,731.601,737.401,703.201,715.70
8th Nov 2019 (Fri)1,721.601,737.001,715.601,732.50
7th Nov 2019 (Thu)1,730.801,737.001,714.401,721.50
6th Nov 2019 (Wed)1,716.601,727.401,665.001,717.40
5th Nov 2019 (Tue)1,747.801,759.801,725.601,730.70
4th Nov 2019 (Mon)1,753.001,767.401,741.401,749.70
1st Nov 2019 (Fri)1,768.801,775.401,749.801,752.90
31st Oct 2019 (Thu)1,777.001,796.401,764.601,775.40
30th Oct 2019 (Wed)1,732.001,788.201,728.401,779.80
29th Oct 2019 (Tue)1,725.201,737.401,714.201,736.00
28th Oct 2019 (Mon)1,702.801,740.001,697.401,736.00
25th Oct 2019 (Fri)1,720.001,720.001,681.001,708.20
24th Oct 2019 (Thu)1,681.801,720.401,680.001,719.70
23rd Oct 2019 (Wed)1,665.001,685.401,656.201,679.60
22nd Oct 2019 (Tue)1,641.001,668.601,633.001,654.90
21st Oct 2019 (Mon)1,644.401,648.601,620.001,641.00
18th Oct 2019 (Fri)1,651.801,660.601,635.001,649.60
17th Oct 2019 (Thu)1,659.001,666.601,629.801,652.80
16th Oct 2019 (Wed)1,666.601,684.001,612.401,639.80

GSK - Glaxosmithkline Investor Summary

GlaxoSmithKline, or 'GSK', is one of the world's leading pharmaceutical companies researching medicines and vacines alike for the World Health Organization's three priority diseases: HIV/AIDS, Malaria and Tuberculosis. With an estimated 7% of the world's pharmaceutical market under its wing, GSK remains one of the industry leaders globally but remains committed to the research and application of life changing and marketable drugs.

If investing in science seems a little confusing and unpredictable then perhaps some of GSK's over-the-counter and more recognisable products will help to convince; these include Gaviscon and Panadol, smoking control products such as Nicorette/Niquitin and nutritional healthcare drinks such as Lucozade, Ribena and Horlicks.

On 23rd January 2009, GSK announced that it had signed an agreement with UCB S.A to acquire its marketed product portfolio in certain parts of the Middle East, Africa, Latin America and Asia Pacific, for a cash consideration of some £484 million. President of Emerging Markets at GSK, Abbas Hussain, said that "This acquisition will strengthen and expand GSK's product portfolio in these countries, helping us to meet the needs of patients, particularly in the areas of epilepsy and respiratory." Under the agreement, GSK acquires several leading pharmaceutical brands and investors will be interested to know that the commercial operations and product distribution rights included represent approximately 3-4% of UCB's 2008 expected revenue of at least £3.09 billion. At the time of Mr Hussain speaking, share prices for GSK were steady at 1,226.00p with a "strong buy" recommendation from brokers.

News about Glaxosmithkline (GSK)

Broker Forecast - Liberum Capital issues a broker note on GlaxoSmithKline PLC

News - Monday, November 04, 2019

Liberum Capital today reaffirms its hold investment rating on GlaxoSmithKline PL......

Broker Forecast - Barclays Capital issues a broker note on GlaxoSmithKline PLC

News - Friday, November 01, 2019

Barclays Capital today reaffirms its equal weight investment rating on GlaxoSmit......

FTSE 100 Latest

Login to your account

Forgot Password?

Not Registered